UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003948
Receipt number R000004746
Scientific Title Randomized phase II trial of UFT plus Cisplatin versus Pemetrexed plus Cisplatin combined with Concurrent Thoracic Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer. North Japan Lung Cancer Study Group Trial 1001 (NJLCG1001)
Date of disclosure of the study information 2010/07/31
Last modified on 2011/03/31 13:06:31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized phase II trial of UFT plus Cisplatin versus Pemetrexed plus Cisplatin combined with Concurrent Thoracic Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer.
North Japan Lung Cancer Study Group Trial 1001 (NJLCG1001)

Acronym

RDM PII UFT+CDDP+RT vs PEM+CDDP+RT
NJLCG1001

Scientific Title

Randomized phase II trial of UFT plus Cisplatin versus Pemetrexed plus Cisplatin combined with Concurrent Thoracic Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer.
North Japan Lung Cancer Study Group Trial 1001 (NJLCG1001)

Scientific Title:Acronym

RDM PII UFT+CDDP+RT vs PEM+CDDP+RT
NJLCG1001

Region

Japan


Condition

Condition

non-small-cell lung cancer

Classification by specialty

Pneumology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To evaluate the efficacy and safety of UFT plus cisplatin versus pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Two-years survival rate

Key secondary outcomes

response rate, progression free survival, overall survival, adverse events


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Patients receive UFT (400mg/m2 per os) on day 1-14 and cisplatin (80mg/m2 div) on day8 every 3 weeks up to 3 cycles combined with concurrent thoracic radiotherapy (66Gy/33Fr)

Interventions/Control_2

Patients receive pemetrexed (500mg/m2 div) on day 1 and cisplatin (80mg/m2 div) on day1 every 3 weeks up to 3 cycles combined with concurrent thoracic radiotherapy (66Gy/33Fr)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Non-squamous non-small-cell lung cancer
2) Chemotherapy-naive
3) Radiotherapy-naive
4) Unresectable locally advanced clinical stage IIIA or IIIB
5) ECOG-PS 0 or 1
6) Measurable lesion by RECIST ver.1.1 criteria
7) Adequate organ function
8) Life expectancy more than 3 months
9) Written informed consent

Key exclusion criteria

1) Clinically active interstitial pneumonia or pulmonary fibrosis, detectable on CT scan
2) Malignant pleural or pericardial effusion or ascites
3) Severe co-morbidities (ex. uncontrolled heart or lung or hepatic or renal disease or diabetes)
4) Regular use of corticosteroid (less than 2 weeks interval after cessation)
5) Pregnancy or lactation, or those who decline contraception
6) Contraindication with chemotherapy or radiotherapy
7) Active concomitant malignancy. Except carcinoma in situ or those who did not relapse 5-years or more
8) Those judged to be not suitable by the attending physician

Target sample size

84


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Makoto Maemondo

Organization

Miyagi Cancer Center

Division name

Dept. of Respiratory Medicine

Zip code


Address

47-1 Nodayama, Medesima-shiote, Natori, Miyagi, Japan. 981-1293

TEL

022-384-3151

Email



Public contact

Name of contact person

1st name
Middle name
Last name Akira Inoue

Organization

Tohoku University Hospital

Division name

Dept. of Respiratory Medicine

Zip code


Address


TEL


Homepage URL


Email

akinoue@idac.tohoku.ac.jp


Sponsor or person

Institute

Miyagi Cancer Center

Institute

Department

Personal name



Funding Source

Organization

Miyagi Cancer Center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

NJLCG 1001

Org. issuing International ID_1

North Japan Lung Cancer Study Group

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 07 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2010 Year 07 Month 20 Day

Date of IRB


Anticipated trial start date

2010 Year 08 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 07 Month 26 Day

Last modified on

2011 Year 03 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004746


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name